DMK Pharmaceuticals Corporation
CY3B
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -99.40% | -82.66% | 25.86% | 285.50% | 98.12% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.40% | -82.66% | 25.86% | 285.50% | 98.12% |
| Cost of Revenue | -79.45% | -47.56% | 22.17% | 49.08% | 5.22% |
| Gross Profit | -132.14% | 45.42% | -8.41% | 88.28% | 82.39% |
| SG&A Expenses | -4.31% | -37.40% | 41.37% | 8.78% | -47.69% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -48.53% | -58.96% | -13.09% | -3.92% | -44.14% |
| Operating Income | 31.97% | 58.85% | 18.77% | 45.16% | 54.72% |
| Income Before Tax | 59.35% | 15.98% | 11.53% | 56.46% | 17.36% |
| Income Tax Expenses | -- | -- | -- | 150.00% | -- |
| Earnings from Continuing Operations | 59.35% | 15.98% | 11.53% | 56.44% | 17.36% |
| Earnings from Discontinued Operations | 372.67% | -2,441.59% | 143.48% | 107.85% | 98.22% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.45% | -2.11% | 13.63% | 62.08% | 64.41% |
| EBIT | 31.97% | 58.85% | 18.77% | 45.16% | 54.72% |
| EBITDA | 27.15% | 58.03% | 16.53% | 47.44% | 57.05% |
| EPS Basic | 90.43% | 13.24% | 15.50% | 62.28% | 64.67% |
| Normalized Basic EPS | 88.51% | 109.28% | -5.76% | 50.17% | 58.34% |
| EPS Diluted | 90.43% | 13.24% | 16.27% | 62.28% | 64.67% |
| Normalized Diluted EPS | 88.51% | 109.28% | -5.76% | 50.17% | 58.34% |
| Average Basic Shares Outstanding | 229.77% | 20.05% | 2.20% | 0.54% | 0.74% |
| Average Diluted Shares Outstanding | 229.77% | 20.05% | 2.20% | 0.54% | 0.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |